Dr Philip Camilleri

MRCP M.D. FRCR.


Special clinical interest in urology; prostate disease including prostate cancer; testicular; bladder; urological oncology treating with IMRT, IGRT and brachytherapy; chemotherapy including docetaxel and cabazitaxel; hormone therapy including abiraterone (Zytiga) and enzalutamide (Xtandi); bone therapy with Zometa and Denosumab.

LANGUAGES

English, Italian, Maltese, French

Professional profile

Dr Philip Camilleri was appointed as Consultant Clinical Oncologist in 2006 having trained in clinical oncology in Oxford. He specialises in urological cancers – specifically prostate, bladder, renal and testicular cancers – and provides chemotherapy, hormonal as well as radiotherapy treatment to cover all situations.

He is involved in research for most urological cancers and has opened up and led on numerous national studies in Oxford.

Dr Camilleri set up the prostate brachytherapy service in Oxford in 2013. He is the lead clinician for the urological oncology multi-disciplinary team at the Churchill Hospital.

NHS Hospital
Consultant Clinical Oncologist, Oxford Cancer Centre and Oxford University Hospitals NHS Trust.

Year Qualified
1995

Professional memberships

MRCP
FRCR
MDU

Qualifications

MRCP M.D. FRCR

Research interests

Technical radiotherapy with brachytherapy, stereotactic hypofractionated radiotherapy, image guided therapy as well as targeted therapy using advanced imaging techniques.

Clinical interests

Special clinical interest in urological cancers with a special interest in prostate cancer. Other tumours treated include testicular; bladder and renal cancer. Radical urological oncology treatments with intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), brachytherapy and stereotactic ablative body radiotherapy (SABR).
Systemic therapy including chemotherapy with docetaxel and cabazitaxel; hormone therapy including abiraterone (Zytiga) and enzalutamide (Xtandi); bone therapy with Radium 223, Zometa and Denosumab. Palliative radiotherapy and SABR for oligometastatic disease.

Awards Received

Kay Fellowship awarded by the Royal College of Radiologists 2013.

Specialities

  • Oncology

Centres